UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of thoracic oncology, ISSN 1556-0864, 10/2016, Volume 11, Issue 10, pp. 1604 - 1605
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 2014, Volume 40, Issue 6, pp. 716 - 722
Hematology, Oncology and Palliative Medicine | Non small cell lung cancer (NSCLC) | Driver oncogenes | Targeted treatment | Brain metastasis | Stereotactic radiotherapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Neurology | Tumors of the nervous system. Phacomatoses | Pharmacology. Drug treatments | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Antineoplastic agents | Tumors | Pneumology | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - genetics | Carcinoma, Non-Small-Cell Lung - surgery | Prognosis | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Radiosurgery | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Treatment Outcome | Brain Neoplasms - drug therapy | Brain Neoplasms - surgery | Incidence | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Molecular Targeted Therapy - methods | Blood-Brain Barrier | Lung cancer, Small cell | Chemotherapy | Metastasis | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Lung cancer (Amsterdam, Netherlands), ISSN 0169-5002, 2012, Volume 77, pp. S2 - S2
Journal Article
The New England journal of medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1700 - 1709
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Lung Neoplasms - pathology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Hyperglycemia - chemically induced | Antineoplastic Agents - adverse effects | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Hyperglycemia | Chemotherapy | Epidermal growth factor | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Genes | Non-small cell lung carcinoma | Antitumor activity | Pharmacokinetics | Patients | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 10, pp. 916 - 917
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Taxoids - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Humans | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Female | Male | Antineoplastic Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Index Medicus
Journal Article
Clinical cancer research, ISSN 1078-0432, 07/2018, Volume 24, Issue 14, pp. 3334 - 3347
Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Humans | Middle Aged | Male | Carcinoma, Non-Small-Cell Lung - diagnosis | Proto-Oncogene Proteins - chemistry | Structure-Activity Relationship | Molecular Targeted Therapy | Biomarkers, Tumor | Anaplastic Lymphoma Kinase - genetics | DNA Copy Number Variations | Young Adult | Protein Kinase Inhibitors - chemistry | Protein-Tyrosine Kinases - genetics | Oncogene Proteins, Fusion - chemistry | Protein-Tyrosine Kinases - chemistry | Adult | Female | Anaplastic Lymphoma Kinase - chemistry | Lung Neoplasms - genetics | Computational Biology - methods | Carcinoma, Non-Small-Cell Lung - genetics | Models, Molecular | In Situ Hybridization, Fluorescence | Proto-Oncogene Proteins - genetics | Drug Resistance, Neoplasm - genetics | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Aged | High-Throughput Nucleotide Sequencing | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Lung Neoplasms - diagnosis | Tyrosine | Neuregulin 1 | Epidermal growth factor receptors | Genes | Lung cancer | Non-small cell lung carcinoma | Drug resistance | Kinases | Patients | ErbB-2 protein | Gene fusion | Genetic screening | Gene sequencing | Polymerase chain reaction | β-catenin | Ret protein | Experimental design | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | DNA sequencing | Cancer | Proto-oncogenes | Index Medicus | non-small cell lung cancer | ALK | tyrosine kinase inhibitor | ROS1 | acquired resistance
Journal Article
Journal of thoracic oncology, ISSN 1556-0864, 12/2013, Volume 8, Issue 12, pp. 1465 - 1466
crizotinib | leptomeningeal carcinomatosis | intramedullary spinal cord metastases | anaplastic lymphoma kinase | Medical University of Gdańsk | Gdańsk | Intramedullary spinal cord metastases | Crizotinib Department of Oncology and Radiotherapy | Poland | Anaplastic lymphoma kinase | Leptomeningeal carcinomatosis | Respiratory System | Oncology | Life Sciences & Biomedicine | Science & Technology | Carcinoma, Non-Small-Cell Lung - pathology | Spinal Neoplasms - secondary | Receptor Protein-Tyrosine Kinases - genetics | Gene Rearrangement | Humans | Female | Lung Neoplasms - pathology | Male | Meningeal Carcinomatosis - secondary
Journal Article
Journal of thoracic oncology, ISSN 1556-0864, 2014, Volume 9, Issue 4, p. S6
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 11/2006, Volume 24, Issue 31, pp. 5034 - 5042
Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Tumors | Pneumology | Immunohistochemistry | Lung Neoplasms - drug therapy | Predictive Value of Tests | Receptor, Epidermal Growth Factor - genetics | Phosphorylation | Proto-Oncogene Proteins p21(ras) | Carcinoma, Non-Small-Cell Lung - chemistry | ras Proteins | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Antineoplastic Agents - therapeutic use | Adult | Female | Lung Neoplasms - chemistry | Biomarkers, Tumor - analysis | In Situ Hybridization, Fluorescence | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Proto-Oncogene Proteins B-raf - genetics | Quinazolines - therapeutic use | Proto-Oncogene Proteins c-akt - analysis | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 02/2020, Volume 21, Issue 2, pp. 261 - 270
Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Benzamides - therapeutic use | Carcinoma, Non-Small-Cell Lung - secondary | Multicenter Studies as Topic | Time Factors | Antineoplastic Agents - adverse effects | Female | Biomarkers, Tumor - antagonists & inhibitors | Benzamides - adverse effects | Lung Neoplasms - genetics | Proto-Oncogene Proteins - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Gene Fusion | Proto-Oncogene Proteins - genetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - therapeutic use | Progression-Free Survival | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Indazoles - adverse effects | Clinical Trials, Phase I as Topic | Indazoles - therapeutic use | Clinical Trials, Phase II as Topic | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 12/2019, Volume 20, Issue 12, pp. 1702 - 1709
Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Prognosis | Prospective Studies | Follow-Up Studies | Mesothelioma - pathology | Humans | Middle Aged | Carboplatin - administration & dosage | Lung Neoplasms - pathology | Male | Survival Rate | Cisplatin - administration & dosage | Mesothelioma - drug therapy | Pleural Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - administration & dosage | Female | Aged | Mesothelioma, Malignant | Pleural Neoplasms - pathology | Care and treatment | Analysis | Carboplatin | Mesothelioma | Product development | Pemetrexed | Tumors | Index Medicus
Journal Article
The lancet respiratory medicine, ISSN 2213-2600, 06/2020, Volume 8, Issue 6, pp. 528 - 529
Journal Article
Cancer treatment reviews, ISSN 0305-7372, 12/2018, Volume 71, pp. 59 - 67
Stereotactic radiosurgery | ALK inhibitors | Brain metastases | EGFR inhibitors | Whole brain radiotherapy | Non-small cell lung cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Crizotinib - therapeutic use | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Brain Neoplasms - drug therapy | Brain Neoplasms - secondary | Protein Kinase Inhibitors - therapeutic use | Crizotinib - pharmacology | Antineoplastic Agents - pharmacology | Brain Neoplasms - mortality | Brain Neoplasms - radiotherapy | Anaplastic Lymphoma Kinase - antagonists & inhibitors | Molecular Targeted Therapy - methods | Oncogenes | Tyrosine | Brain | Chemotherapy | Radiosurgery | Phenols | Lung cancer, Small cell | Metastasis | Lung cancer, Non-small cell | Health aspects | Cancer | Index Medicus
Journal Article